TearLab Corporation operates as an in-vitro diagnostic company in the United States and internationally. The company offers TearLab Osmolarity System, a proprietary in vitro diagnostic tear testing platform that measures tear film osmolarity for the diagnosis of dry eye disease; and enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. Its TearLab Osmolarity System consists of TearLab disposable, a single-use microfluidic microchip; TearLab Pen, a hand-held device that interfaces with the TearLab disposable; and TearLab Reader, a small desktop unit that allows for the docking of the TearLab Pen, as well as provides a quantitative reading for the operator. The company was formerly known as OccuLogix, Inc. TearLab Corporation was founded in 1996 and is headquartered in Southlake, Texas. As of 1 Jan 2022 TearLab Corporation was acquired by Trukera Medical